공시 • Apr 28
iFabric Corp., Annual General Meeting, Jun 29, 2026 iFabric Corp., Annual General Meeting, Jun 29, 2026. Location: ontario, markham Canada 공시 • Aug 22
iFabric Corp. Announces Publication of Groundbreaking Clinical Trial Providing the Infection Convenience Capability of PROTX2 and ecoPEL Treated Scrubs iFabric Corp. announced that the results of its clinical trial, "Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs, has been officially published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience. The study-conducted by subsidiary Intelligent Fabric Technologies (North America) Inc. "IFTNA" at MemorialCare Saddleback Medical Center in Southern California under the leadership of Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA, FAHA, FAAN;leen M. Young, MSN, RN, NPD-BC;andi Cassingham, MSN, RN; and Lisa Forsythe, MSN-Ed, RN, NPD- BC-marks the first successful antimicrobial textile trial of its kind to demonstrate statistically significant reductions in bacterial loads on scrubs worn in a real-world healthcare setting. This trial conclusively showed that scrubs treated with PROTX2 and PROTX2 combined with ecoPEL Fluorine-Free Durable Water Repellent (DWR) technology achieved significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs -proof that these proprietary technologies can deliver infection control performance unmatched in the industry. As a nonprofit, all revenue is reinvested into patient care, technology, and facility improvements, supported by the Saddleback Medical Center Foundation, which has fostered community partnership and philanthropy since founding. With over 500 affiliated clinicians, the company provide a full spectrum of inpatient, surgical, and outpatient services-including urgent care, advanced imaging, joint replacement, infusion therapy, stroke care, and rehabilitation-ensuring accessible, high-quality care for every stage of life. At Saddleback Medical Center, compassionate care, medical excellence, and community partnership remain at the heart of its mission. 공시 • May 08
iFabric Corp. to Report Q1, 2025 Results on May 15, 2025 iFabric Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025 공시 • Apr 23
iFabric Corp., Annual General Meeting, Jun 24, 2025 iFabric Corp., Annual General Meeting, Jun 24, 2025. Location: ontario, markham Canada 공시 • Mar 14
iFabric Corp. Provides Sales Guidance for the Full Year 2024 iFabric Corp. provided Sales guidance for the full year 2024. For the year, the company expects sales to the range of $28 million to $32 million. 공시 • Nov 10
iFabric Corp. Announces Expansion Move iFabric Corp. announced that it has executed a lease agreement for the rental of approximately 5,000 square feet of office space in Markham, Ontario, at a commercial office building near its current head office and warehouse location. The new offices will house the Canadian management and administrative personnel of the Company. After the move, the current Company owned building located at 525 Denison Street, Markham, Ontario, which currently comprises a mix of warehouse and office space, will be fully repurposed as warehouse space. The new office lease agreement is for a period of 5 years commencing on April 1, 2024, and expiring March 31, 2029, with the option to renew for a further period of 5 years. iFabric's personnel will be occupying temporary space at the new location, until such time as the required leasehold improvements to its new premises have been completed. 공시 • Jul 06
iFabric Corp. Announces the Successful Results of the Clinical Trial Utilizing Protx2 Treated Scrubs iFabric Corp. provided an update on the outcome of the clinical trial conducted by its wholly-owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"). The objective of the trial was to empirically demonstrate the reduction in bacterial loads on PROTX2 treated scrubs vs standard off the shelf untreated scrubs, when used in a healthcare environment. Three sets of scrubs were produced for the trial; one set treated with ProTX2 only, a second set with Protx2 and proprietary DWR (durable water repellant) technology and, a third set with no technologies applied (the control). The summary of the trial findings is that both the PROTX2 and the PROTX2 with DWR treated scrubs demonstrated statistically significant reductions in bacterial loads on the surfaces of scrubs, as compared to untreated scrubs. The term statistically significant is used to describe a result that is highly unlikely to occur by chance alone in a natural environment. The results achieved in the study demonstrate that proprietary technologies were uniquely responsible for the reduction in bacterial loads witnessed throughout the trial. The next and final phase of this trial is to submit the study to a recognized medical journal for peer review.